FindTrial
Sign In

Enoblituzumab

DRUG7 trials

Sponsors

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, MacroGenics, Masonic Cancer Center, University of Minnesota

Conditions

CancerDesmoplastic Small Round Cell TumorEwing SarcomaFallopian Tube AdenocarcinomaFallopian Tube CancerHead and Neck CancerHead and Neck NeoplasmsHead and Neck Squamous Cell Carcinoma

Phase 1

Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors
CompletedNCT02982941
MacroGenicsDesmoplastic Small Round Cell Tumor, Ewing Sarcoma, Neuroblastoma +3
Start: 2016-12-31End: 2019-05-22Updated: 2022-02-08
FT516 and IL2 With Enoblituzumab for Ovarian Cancer
CompletedNCT04630769
Masonic Cancer Center, University of MinnesotaFallopian Tube Adenocarcinoma, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Start: 2021-04-02End: 2022-01-01Updated: 2023-04-03
MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
TerminatedNCT05708924
Masonic Cancer Center, University of MinnesotaCancer, Fallopian Tube Cancer, Ovarian Cancer +2
Start: 2023-04-28End: 2024-08-06Updated: 2025-08-14

Phase 2

Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer
Active, not recruitingNCT02923180
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsProstate Cancer
Start: 2017-02-14End: 2027-07-01Updated: 2026-08-21
Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck
WithdrawnNCT04129320
MacroGenicsHead and Neck Cancer, Squamous Cell Carcinoma of Head and Neck
Start: 2019-10-31End: 2022-10-31Updated: 2022-02-08
Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer
TerminatedNCT04634825
MacroGenicsHead and Neck Cancer, Head and Neck Neoplasms, Head and Neck Squamous Cell Carcinoma
Start: 2021-03-17End: 2022-07-29Updated: 2023-12-20
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
Active, not recruitingNCT06014255
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsProstate Cancer
Start: 2024-02-16End: 2029-03-01Target: 219Updated: 2026-07-24

Related Papers

A phase 2 randomized trial of neoadjuvant enoblituzumab versus standard of care in men with high-risk localized prostate cancer: The help elucidate and attack longitudinally (HEAT) prostate cancer randomized study.
Journal of Clinical Oncology2024-06-011 citations
Enoblituzumab Study Reveals Clinical Activity in Prostate Cancer
Oncology Times2023-06-04
Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial.
2023-04-0380 citations
Targeting B7-H3 in prostate cancer: Phase 2 trial in localized prostate cancer using the anti-B7-H3 antibody enoblituzumab, with biomarker correlatives.
Journal of Clinical Oncology2022-06-013 citations
Phase 2 trial of enoblituzumab plus retifanlimab or tebotelimab in first-line treatment of patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).
Journal of Clinical Oncology2022-06-013 citations
Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial
Journal for ImmunoTherapy of Cancer2022-04-01130 citations
Antibodies to watch in 2020.
2020-01-01328 citations
Phase II neoadjuvant and immunologic study of B7-H3 targeting with enoblituzumab in localized intermediate- and high-risk prostate cancer.
Journal of Clinical Oncology2018-05-2015 citations
A phase 1, open-label, dose escalation study of enoblituzumab (MGA271) in pediatric patients with B7-H3-expressing relapsed or refractory solid tumors.
Journal of Clinical Oncology2017-05-2018 citations